Harvard Bioscience Announces Preliminary Fourth Quarter Financial Results, Positive Outlook for 2026 & Outlines Long-Term Strategic Focus Areas

Reports preliminary fourth quarter revenue in line with guidance, gross margin at high end of guidance, and strong year over year adjusted EBITDA performance Expects year over year revenue growth and mid-to high-single-digit EBITDA growth in 2026 Outlines strategy focused on positioning the company as a leader in the growing translational science tools market while expanding consumables revenue and improving operational performance HOLLISTON, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), a global leader in life science research tools, today announced preliminary financial results for the fourth quarter ended December 31, 2025.

GlobeNewsWire • Feb 10, 2026

Harvard Bioscience Announces Strategic Consolidation of Manufacturing Operations to Improve Efficiency and Support Long-Term Growth

Streamlining production footprint and improving manufacturing efficiency through phased closure of Holliston, MA plant  Initiative expected to deliver approximately $3 million in cost savings in 2027 and $4 million in annual cost savings beginning in 2028 while improving throughput and execution HOLLISTON, Mass., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), today announced a strategic consolidation of its manufacturing operations designed to enhance operational efficiency, strengthen execution, and accelerate cost-savings efforts.

GlobeNewsWire • Jan 29, 2026

Harvard Bioscience Announces the Successful Completion of Debt Refinancing with Comprehensive Growth Financing Package

Completes Repayment of Existing Credit Agreement, Extends Debt Maturity, and Enhances Financial Flexibility BroadOak Partner Bill Snider to Join Board of Directors and Company to Form Advisory Board on Growth and Operating Opportunities  HOLLISTON, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), today announced it entered into an agreement with BroadOak Capital Partners (collectively, “BroadOak”), a life-sciences-focused investment and advisory firm, to provide a $40 million credit facility comprised of three term loans, all of which will be funded on December 17, 2025.

GlobeNewsWire • Dec 17, 2025

Harvard Bioscience, Inc. (HBIO) Q3 2025 Earnings Call Transcript

Harvard Bioscience, Inc. ( HBIO ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants John Duke - President, CEO & Director Mark Frost - Interim CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer Conference Call Participants Taylor Krafchik Lucas Baranowski - KeyBanc Capital Markets Inc., Research Division Bruce Jackson - The Benchmark Company, LLC, Research Division Presentation Operator Good day, and welcome to the Third Quarter 2025 Harvard Bioscience Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded.

Seeking Alpha • Nov 7, 2025

Harvard Bioscience Announces Third Quarter 2025 Financial Results

Reports Q3 2025 Revenues of $20.6M, Gross Margin of 58.4%, and Positive Cash Provided by Operations Company Expects to Refinance or Repay the Debt in the Fourth Quarter Fourth Quarter 2025 Guidance Reflects Increased Demand and Backlog, Improved Operations and Strong Financial Discipline HOLLISTON, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the third quarter and nine months ended September 30, 2025.

GlobeNewsWire • Nov 6, 2025

Harvard Bioscience Schedules Third Quarter 2025 Earnings Conference Call for November 6, 2025 at 8:00 AM ET

HOLLISTON, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2025, before the market opens on November 6, 2025, and will hold a conference call to discuss the results at 8:00 a.m.

GlobeNewsWire • Oct 30, 2025

Harvard Bioscience Expands Distribution Agreement with Fisher Scientific to Include United States

HOLLISTON, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), a leading provider of innovative laboratory equipment, is pleased to announce the expansion of its distribution agreement with Fisher Scientific, a part of Thermo Fisher Scientific, one of the world's largest and most trusted scientific suppliers.

GlobeNewsWire • Sep 16, 2025

Harvard Bioscience Announces Appointment of Stephen DeNelsky to Board of Directors

HOLLISTON, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced the appointment of Stephen DeNelsky to its Board of Directors, effective September 5, 2025.

GlobeNewsWire • Sep 9, 2025

Harvard Bioscience, Inc. (HBIO) Q2 2025 Earnings Call Transcript

Harvard Bioscience, Inc. (NASDAQ:HBIO ) Q2 2025 Earnings Conference Call August 11, 2025 8:00 AM ET Company Participants John Duke - President, CEO & Director Mark T. Frost - Interim CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer Conference Call Participants Bruce David Jackson - The Benchmark Company, LLC, Research Division Paul Richard Knight - KeyBanc Capital Markets Inc., Research Division Taylor Krafchik - Unidentified Company Operator Good day, and welcome to the Second Quarter 2025 Harvard Bioscience Earnings Conference Call.

Seeking Alpha • Aug 11, 2025

Harvard Bioscience Announces Second Quarter 2025 Financial Results

Reports Q2 2025 Revenues of $20.5M, Gross Margin of 56.4%, and Positive Cash Provided by Operations Third Quarter 2025 Guidance Reflects Improved Operations and Strong Financial Discipline New Credit Amendment Signed, Extending Refinance Deadline to December 5th HOLLISTON, Mass., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the second quarter and six months ended June 30, 2025.

GlobeNewsWire • Aug 11, 2025